ClinicalTrials.gg
CompletedNCT00344370Updated Feb 2, 2010Results posted

Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

A Phase 3 interventional study of Pitavastatin and Atorvastatin in Type II Diabetes Mellitus and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 35 sites in 6 countries. Per ClinicalTrials.gov, last updated 2010-02-02.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 28 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.

Enrollment
271st of 333
214 · median 500
Started
2006
with 20 others
Phase 3
218 of 351
16 open now
Registered
40th of 351
by date

Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 271st largest by enrollment of the 333 interventional ones that give a count, is one of 21 that started in 2006, is one of 218 in phase 3, and was the 40th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, or all of them as a file.
02

Study summary

This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.

03

Conditions studied

  • Type II Diabetes Mellitus
  • Dyslipidemia

Keywords

  • Pitavastatin
  • Type II Diabetes Mellitus
  • Combined Dyslipidemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type II diabetes mellitus
  • Combined dyslipidemia
  • Completed NK-104-305 (NCT00309751)

Exclusion criteria

Exclusion Criteria:

  • Withdrawal from NK-104-305 (NCT00309751)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Pitavastatin

    Pitavastatin 4 mg QD

    Drug: Pitavastatin

  • Active comparator
    Atorvastatin

    Atorvastatin 40 mg

    Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. NCEP LDL-C Target Attainment

    Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at 44 weeks. According to NCEP criteria the target LDL-C is 100 mg/dL for all patients in this study.

    Time frame: 44 weeks

Secondary outcomes

  1. Percent Change From Baseline in LDL-C

    Percent change from baseline in LDL-C at 44 weeks

    Time frame: Basseline to 44 weeks

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 4 mgAtorvastatin 40 mg
Started14371
Completed12868
Not completed153

Outcome measures

PrimaryNCEP LDL-C Target Attainment

Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at 44 weeks. According to NCEP criteria the target LDL-C is 100 mg/dL for all patients in this study.

Time frame:
44 weeks
Reported as:
Number · Participants
NCEP LDL-C Target Attainment
ParticipantsPitavastatin 4 mgAtorvastatin 40 mg
NCEP LDL-C Target Attainment11055
SecondaryPercent Change From Baseline in LDL-C

Percent change from baseline in LDL-C at 44 weeks

Time frame:
Basseline to 44 weeks
Reported as:
Mean · percent change
Percent Change From Baseline in LDL-C
percent changePitavastatin 4 mgAtorvastatin 40 mg
Percent Change From Baseline in LDL-C-40.98 ± 19.053-41.43 ± 21.159

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg—8/143 (5.6%)22/143 (15.4%)
Atorvastatin 40 mg—5/71 (7%)15/71 (21.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPitavastatin 4 mgAtorvastatin 40 mg
Acute coronary syndromeCardiac disorders1/1431/71
Abdominal painGastrointestinal disorders0/1431/71
Bacterial pyelonephritisInfections and infestations0/1431/71
UrosepsisInfections and infestations0/1431/71
Myalgia intercostalMusculoskeletal and connective tissue disorders0/1431/71
EpilepsyNervous system disorders0/1431/71
Angina pectorisCardiac disorders1/1430/71
CardiomyopathyCardiac disorders1/1430/71
Myocardial infarctionCardiac disorders1/1430/71
Food poisoningGastrointestinal disorders1/1430/71
Most frequent other events
Most frequent other events
EventPitavastatin 4 mgAtorvastatin 40 mg
Myalgia/myalgia intercostalMusculoskeletal and connective tissue disorders6/1435/71
NaspopharyngitisMusculoskeletal and connective tissue disorders10/1432/71
ArteriosclerosisVascular disorders4/1434/71
Diabetes mellitus inadequate controlMetabolism and nutrition disorders2/1434/71

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mgAtorvastatin 40 mgTotal
<=18 years000
Between 18 and 65 years9546141
>=65 years482573
Age Continuous
Age Continuous(years)Pitavastatin 4 mgAtorvastatin 40 mgTotal
Mean59.3 ± 9.8360.0 ± 9.2159.5 ± 9.61
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mgAtorvastatin 40 mgTotal
Female683098
Male7541116
08

Study locations

35 sites
  • CCBR Aalborg
    Aalborg, Denmark
  • CCBR A/S
    Vejle, Denmark
  • CCBR Vejle
    Vejle, Denmark
  • Gemeinschaftspraxis am Bahnhof
    Berlin-Spandau, Germany
  • Pharmakologisches Studienzentum Chemnitz
    Chemnitz, Germany
  • Internistische Diabetische Schwerpunktpraxis Dr.
    Frankfurt Am Main, Germany
  • Internistische Gemeinschaftspraxis
    Mainz, Germany
  • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
    Messkirch, Germany
  • Bhagwan Mahaveer Jain Heart Centre
    Bangalore, India
  • Sri Ramachandra Medical College Hospital
    Chennai, India
  • Apollo Hospitals
    Hyderabaad, India
  • CARE Group of Hospitals
    Hyderabaad, India
  • PD Hinduja Hospital
    Mumbai, India
  • Andromed Breda
    Breda, Netherlands
  • Andromed Eindhoven
    Eindhoven, Netherlands
  • Andromed Noord
    Groningen, Netherlands
  • Andromed Leiden
    Leiden, Netherlands
  • Andromed Nijmegen
    Nijmegen, Netherlands
  • Andromed Rotterdam
    Rotterdam, Netherlands
  • Andromed Oost
    Velp, Netherlands
  • Andromed Zoetermeer
    Zoetermeer, Netherlands
  • Podlaski Osrodek Kardiologii
    Bialystok, Poland
  • NZOZ GCP Dobra Praktyka Lekaska
    Gruziadz, Poland
  • NZOZ Terapia Optima
    Katowice, Poland
  • NZOZ Esculap, Przychodnia Lekary Rodzinnych
    Losice, Poland
  • NZOZ Centrum, Poradnia Kardiologiczna
    Siedlce, Poland
  • Spec. Gab. Lek. Internistyczno-Kardiologicznly
    Tarnow, Poland
  • Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
    Tychy, Poland
  • Instytut Zywnosci i Zywienia
    Warszawa, Poland
  • Lecznica PROSEN SMO
    Warszawa, Poland
  • Szpital Wolski,im. Dr A. Gostynskiej
    Warszawa, Poland
  • Synexus Reading Clinical Research Centre
    Berkshire, United Kingdom
  • Synexus Lancashire Clinical Research Centre
    Lancashire, United Kingdom
  • Synexus Merseyside Clinical Research Centre
    Liverpool, United Kingdom
  • Synexus Manchester Clinical Research Centre
    Manchester, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2006
First posted
Jun 26, 2006
Start
Aug 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jan 18, 2010
Last update
Feb 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00344370
First posted
Jun 26, 2006
Start date
Aug 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jan 18, 2010
Last update
Feb 2, 2010

Study contacts

Dragos Budinski, MD
study director · Kowa Research Europe (KRE)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion